JPM vs RAND
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
RAND exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a completely bearish technical trend (0/100). While the stock trades at a discount to book value (P/B 0.61), this is offset by a catastrophic profit margin of -124.17% and a significant revenue contraction of -39.90% YoY. The high dividend yield of 10.74% appears unsustainable given the lack of earnings growth and negative ROE. Overall, the data suggests a value trap where low valuation metrics are a reflection of deteriorating fundamental health.
Compare Another Pair
Related Comparisons
JPM vs RAND: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Rand Capital Corporation (RAND) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.